• Type of Event: The document is a transcript of the Q2 and H1 FY 2027 Earnings Conference Call held on October 30, 2026.
  • Date and Time: The call was held on October 30, 2026. A specific time and time zone were not mentioned in the provided transcript.
  • Purpose: The purpose of the call was to discuss the company's Un-audited Financial Results (Standalone and Consolidated) for the second quarter and half year ended September 30, 2026, and to provide a business update.
  • Management Participants: The management participants on the call were Mr. Ashish Gaikwad (Managing Director) and Mr. Sachin Raole (Joint Managing Director and Chief Financial Officer). The call was moderated by a representative from Valorem Advisors, Ms. Purvangi Jain.
  • Financial Period Discussed: The discussion centered on the financial results for Q2 (quarter ended September 30, 2026) and H1 (half year ended September 30, 2026) of FY 2027.
  • Forward-Looking Statements: The opening remarks included a cautionary statement that some forward-looking statements may be made during the call, which are subject to risks and uncertainties. The management discussed several strategic themes and opportunities, including the development of international bioenergy projects (~INR 1000 crore pipeline), the growth of the GenX business (precision fabrication for data centers, oil & gas), the new Compressed Biogas (CBG) joint venture with BPCL, and progress on new biofuels like Sustainable Aviation Fuel (SAF) and bio-isobutanol (bio-IBA).
  • Compliance Language: The initial letter states the information is provided pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015. The cautionary statement at the beginning of the call noted that the purpose was "purely to educate and bring awareness" and advised listeners not to place "undue reliance" on forward-looking statements.

Financial & Operational Highlights from Transcript

Q2 FY27 Financials (Consolidated):

  • Income from Operations: INR 8.49 billion (vs. INR 8.42 billion in Q2 FY26)
  • Profit Before Tax (PBT): INR 361 million (vs. INR 296 million in Q2 FY26)
  • Profit After Tax (PAT): INR 231 million (vs. INR 192 million in Q2 FY26)

H1 FY27 Financials (Consolidated):

  • Income from Operations: INR 15.6 billion (vs. INR 14.8 billion in H1 FY26)
  • Profit Before Tax (PBT): INR 571 million (vs. INR 392 million in H1 FY26)
  • Profit After Tax (PAT): INR 347 million (vs. INR 246.2 million in H1 FY26)

Business Mix (Q2 FY27):

  • Export Revenues: 38% of total revenue
  • Revenue by Segment: Bioenergy (69%), Engineering (21%), PHS (10%)

Order Intake & Backlog (Q2 FY27):

  • Order Intake: INR 7.15 billion (62% domestic, 38% international)
  • Order Intake by Segment: Bioenergy (57%), Engineering (26%), PHS (17%)
  • Order Backlog (as of Sept 30, 2026): INR 44.6 billion (63% domestic orders)

Cash Position:

  • Cash in hand as of September 30, 2026: INR 5.33 billion

Key Business Updates:

  • CBG JV: The board has given in-principle approval to invest up to INR 100 crores in a proposed JV with BPCL for setting up new CBG plants.
  • GenX Business: The Mangaluru facility is approved by 18 international customers. Four framework agreements are operational. The business is seeing orders in data center precision fabrication.
  • New Biofuels: Progress is being made on India's first bio-IBA plant, with construction expected to be completed by end of CY 2026. The detailed engineering package for an ethanol-to-SAF plant for an international customer is progressing, with a Final Investment Decision (FID) expected in Q1 FY28.

Additional Notes Section

  • The document is the enclosed transcript of the analysts' call, as referenced in the introductory letter from the Company Secretary.
  • The transcript contains the full Q&A session with analysts, covering topics such as margin outlook, order inflow trajectory, GenX business breakeven expectations, and details of the CBG JV strategy.
  • No standalone financial data was presented in the transcript excerpt; all figures discussed were consolidated.
  • The tone of the disclosure is neutral and informative, serving as a scheduled post-earnings engagement.